JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) EV-to-EBIT : 16.15 (As of Sep. 26, 2024)

View and export this data going back to 2021. Start your Free Trial

What is JSP Pharmaceutical Manufacturing (Thailand) PCL EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, JSP Pharmaceutical Manufacturing (Thailand) PCL's Enterprise Value is ฿1,295.6 Mil. JSP Pharmaceutical Manufacturing (Thailand) PCL's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was ฿80.2 Mil. Therefore, JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-EBIT for today is 16.15.

The historical rank and industry rank for JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-EBIT or its related term are showing as below:

BKK:JSP' s EV-to-EBIT Range Over the Past 10 Years
Min: -569.4 Med: 48.13 Max: 202.79
Current: 16.14

During the past 5 years, the highest EV-to-EBIT of JSP Pharmaceutical Manufacturing (Thailand) PCL was 202.79. The lowest was -569.40. And the median was 48.13.

BKK:JSP's EV-to-EBIT is ranked worse than
60.78% of 1540 companies
in the Consumer Packaged Goods industry
Industry Median: 13.53 vs BKK:JSP: 16.14

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. JSP Pharmaceutical Manufacturing (Thailand) PCL's Enterprise Value for the quarter that ended in Jun. 2024 was ฿2,324.5 Mil. JSP Pharmaceutical Manufacturing (Thailand) PCL's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was ฿80.2 Mil. JSP Pharmaceutical Manufacturing (Thailand) PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 3.45%.

JSP Pharmaceutical Manufacturing (Thailand) PCL EV-to-EBIT Historical Data

The historical data trend for JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JSP Pharmaceutical Manufacturing (Thailand) PCL EV-to-EBIT Chart

JSP Pharmaceutical Manufacturing (Thailand) PCL Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

60.62

230.20

46.15

JSP Pharmaceutical Manufacturing (Thailand) PCL Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
EV-to-EBIT	Get a 7-Day Free Trial											145.44	36.37	46.15	48.13	28.97

Competitive Comparison of JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-EBIT

For the Packaged Foods subindustry, JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-EBIT falls into.

JSP Pharmaceutical Manufacturing (Thailand) PCL EV-to-EBIT Calculation

JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1295.609	/	80.24
	=	16.15

JSP Pharmaceutical Manufacturing (Thailand) PCL's current Enterprise Value is ฿1,295.6 Mil.
JSP Pharmaceutical Manufacturing (Thailand) PCL's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿80.2 Mil.

JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

JSP Pharmaceutical Manufacturing (Thailand) PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 )	=	EBIT	/	Enterprise Value (Q: Jun. 2024 )
	=	80.24	/	2324.4905
	=	3.45 %

JSP Pharmaceutical Manufacturing (Thailand) PCL's Enterprise Value for the quarter that ended in Jun. 2024 was ฿2,324.5 Mil.
JSP Pharmaceutical Manufacturing (Thailand) PCL's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿80.2 Mil.

JSP Pharmaceutical Manufacturing (Thailand) PCL EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of JSP Pharmaceutical Manufacturing (Thailand) PCL's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

JSP Pharmaceutical Manufacturing (Thailand) PCL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 255 and 257, Soi Sathupradit, 58, Bang Pongphang, Yannawa, Bangkok, THA, 10120

Website

https://www.jsppharma.com

JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing drugs, dietary supplements, cosmetics, herbs, and dietary supplements in the form of vitamins including healthy coffee Ready. Its segments include Manufacturing and distribution of products under the customer's Brand name and Own Brand name; Manufacture and distribution of hemodialysis solution and related medical supplies and Service, research and development, and healthcare products training. The majority of the revenue comes from the manufacturing and distribution of products under the customer's brand name. The Group is managed and operates principally in Thailand.

JSP Pharmaceutical Manufacturing (Thailand) PCL Headlines

No Headlines